「for」の検索結果
125件：116～120件目を表示
-
お知らせ | 千寿製薬株式会社
2025年12月22日 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel sub...
http://www.senju.co.jp/chinese/news/ -
お知らせ | 千寿製薬株式会社
December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation chann...
https://www.senju.co.jp/english/news/ -
お知らせ | 千寿製薬株式会社
December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation chann...
http://www.senju.co.jp/english/news/ -
Milestones in Our History | About Senju | SENJU Pharmaceutical
ished the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen. July Injection Product for Neutropenia, "PANILTIN", sales launched 1949 February Reishin Tanimura became the Pres...
https://www.senju.co.jp/english/about/history.html -
Product Development Policy | Research & Development | SENJU Pharmaceutica
obial ophthalmic solutions, non-steroidal anti-inflammatory ophthalmic solutions, therapeutic drugs for spring catarrh (orphan drugs), therapeutic drugs for glaucoma, ocular hypertension, etc. We also...
http://www.senju.co.jp/english/rd/policy/